Clene (CLNN) EBITDA Yield: History & Chart

Clene Inc.(CLNN)

Biotechnology · Salt Lake City, UT

$3.95+0.04 (+1.02%)

Delayed quote: Oct 6, 2026, 11:34 AM EDT

About Clene Inc.

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.

Salt Lake City, UT

78 employees

clene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Etherington

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Clene Inc. (CLNN)	$50.47M	N/A	N/A	N/A	N/A
Envoy Medical, Inc. (COCH)vs ›	$51.03M	N/A	0.59%	0.59%	0.59%
Celularity Inc. (CELU)vs ›	$49.79M	N/A	N/A	N/A	N/A
INmune Bio, Inc. (INMB)vs ›	$51.18M	N/A	3.11%	2.71%	2.71%
Microbot Medical Inc. (MBOT)vs ›	$51.27M	N/A	0.89%	5.54%	4.70%
Apollomics, Inc. (APLM)vs ›	$51.39M	N/A	N/A	N/A	N/A
Dogwood Therapeutics, Inc. (DWTX)vs ›	$51.45M	N/A	N/A	N/A	N/A
biote Corp. (BTMD)vs ›	$51.83M	10.99%	20.03%	16.76%	21.84%
Eloxx Pharmaceuticals, Inc. (ELOX)vs ›	$51.91M	N/A	N/A	N/A	N/A
eXoZymes, Inc. (EXOZ)vs ›	$51.98M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Clene Inc. (CLNN)

$50.47M

N/A

Envoy Medical, Inc. (COCH)vs ›

$51.03M

N/A

0.59%

Celularity Inc. (CELU)vs ›

$49.79M

N/A

INmune Bio, Inc. (INMB)vs ›

$51.18M

N/A

3.11%

2.71%

Microbot Medical Inc. (MBOT)vs ›

$51.27M

N/A

0.89%

5.54%

4.70%

Apollomics, Inc. (APLM)vs ›

$51.39M

N/A

Dogwood Therapeutics, Inc. (DWTX)vs ›

$51.45M

N/A

biote Corp. (BTMD)vs ›

$51.83M

10.99%

20.03%

16.76%

21.84%

Eloxx Pharmaceuticals, Inc. (ELOX)vs ›

$51.91M

N/A

eXoZymes, Inc. (EXOZ)vs ›

$51.98M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

CLNN EBITDA Yield Metrics

CLNN Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics